Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04547985 · ClinicalTrials.gov registry record · Phase 4
Naltrexone Treatment for Prolonged Grief Disorder (PGD)
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT04547985 is a Phase 4 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 9 participants.
The verdict
NCT04547985, a Phase 4 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
Interventions
- DRUG Placebo
- DRUG Naltrexone HCl 50 MG Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2023-10-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04547985
The ClinicalTrials.gov registry entry for NCT04547985 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04547985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04547985 about?
NCT04547985 is a clinical study titled "Naltrexone Treatment for Prolonged Grief Disorder (PGD)". This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
What is the current status of trial NCT04547985?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2021-01-05. Estimated completion is 2023-10-16.
What interventions are being tested in trial NCT04547985?
The interventions under investigation include: Placebo (DRUG), Naltrexone HCl 50 MG Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT04547985?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.